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[57] ABSTRACT 
A method for diagnosing a neurological disease com 
prising detecting a neurological disease-speci?c bio 
chemical marker macromolecule within a sample of 
extracted cerebral spinal ?uid is disclosed. In particular, 
a radioactively labeled photoaf?nity probe is used to 
diagnose a neurological disease. For instance, Alzhei 
mer’s disease can be diagnosed by detecting a disease 
speci?c protein having a molecular weight of about 
42,000 daltons, i.e., glutamine synthetase. 
15 Claims, No Drawings 
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DETECTION OF ALZHEIMER’S DISEASE AND 
OTHER DISEASES USING A PHOTOAFFINITY 
LABELING METHOD 
FIELD OF THE INVENTION 
The present invention relates to novel compositions, 
methods and test kits which use the procedure of pho 
toaf?nity labeling with nucleotide affinity probes, to 
detect neurological disease using cerebral spinal ?uid, 
blood, tissue, or other specimens in a mammal. The 
present invention provides a method of diagnosis based 
on a disease-speci?c biochemical marker macromole 
cule which, if present, can be identi?ed in a small bio 
logical sample from ya patient. In particular, the present 
invention concerns a method for diagnosing Alzhei 
mer’s disease using a disease-speci?c nucleotide binding 
protein and detecting the binding of that protein in the 
cerebral spinal ?uid of a patient af?icted with Alzhei 
mer’s disease. 
BACKGROUND OF THE INVENTION 
Alzheimer’s disease (AD) is an idiopathic progressive 
dementia that will affect a large percentage of our aging 
population. To date its etiology is still unknown. The 
neurodegenerative disease is characterized by a chroni 
cally deteriorating course of impaired intellectual func 
tion and memory loss. 
Relatively little is known of the pathophysiological 
chain of events that leads to the premature dysfunction 
and death of affected neurons in Alzheimer’s disease 
patients. Multiple abnormalities have been reported in 
the brains of patients who have been diagnosed as hav 
ing Alzheimer’s disease, but it is difficult to determine 
which of these are the result of brain damage and which 
contribute to premature neuronal dysfunction and 
death. - 
At the present time, the clinical diagnosis of Alzhei 
mer’s disease is one of exclusion. Secondary causes of 
loss of memory and impaired cognitive function may 
result from multiple infarcts, leading to so-called multi 
infarct dementia, or from intracranial mass lesions, such 
as subdural hematomas, brain tumors, or granulomas. 
Central nervous system infections of viral and bacterial 
origin, or even slow viral disorders such as Creutzfeldt 
Jakob disease. are part of the differential diagnosis. 
Furthermore, metabolic disorders involving vitamin 
B12 metabolism, thiamine or folate de?ciency, thyroid 
dysfunction, hepatic and renal failure, as well as drug 
toxicity may appear as dementia. Nevertheless, when all 
these secondary ‘causes, many of which are reversible, 
are eliminated, cerebral atrophy of unknown cause or 
Alzheimer’s disease still covers the largest number of 
patients. 
The de?nitive diagnosis of Alzheimer’s disease is 
made by pathologic examination of postmortem brain 
tissue in conjunction with a clinical history of dementia. 
This diagnosis is based on the presence in brain tissue of 
intraneuronal neuro?brillary tangles and of neuritic 
(senile) plaques, which have been correlated with clini 
cal dementia. Although the cause of the abnormal cy 
toskeletal ?brils remains unknown, neuritic plaques are 
thought to be composed of degenerating axons and 
nerve terminals as well as possible astrocytic elements, 
and they often exhibit a central amyloid protein core. 
The neuro?brillary tangles are interneuronal aggregates 
composed of normal and paired helical ?laments and 
presumably consist of several different proteins. The 
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neurohistopathologic identi?cation and counting of 
neuritic plaques and neuro?brillary tangles requires 
staining and microscopic examination of several brain 
sections. 
It is problematic, however, that histochemical stain 
ing is not always reproducible, neuritic plaques and 
neuro?brillary tangles are not uniformly distributed, 
and histopathologic studies are time-consuming and 
labor-intensive. Moreover, there is no direct evidence 
that an accumulation of abnormal cytoskeletal ?brils 
contributes directly to premature dysfunction and death 
of the neurons; rather, the ?brils may simply be a mani 
festation of more fundamental cellular changes. The 
clinical and pathologic progression of Alzheimer’s dis 
case is marked by a continuing loss of neurons from the 
cerebral cortex. However, neuritic plaques and neuro? 
brillary tangles may occur in nondemented elderly pa 
tients, as well as those afflicted with Alzheimer’s dis 
ease. 
Current research to develop both an understanding of 
the disease and a possible diagnostic test has centered on 
the amyloid protein and its precursor protein. Theoreti 
cally, diagnosis has been based on the deposition of 
amyloid containing plaques in the cortical region in the 
brain of individuals affected with Alzheimer’s disease. 
Such diagnostic methods have been disclosed in, for 
example, U.S. Pat. No. 4,666,829, 4,701,407, 4,816,416 
and 4,933,156. 
However, amyloid deposits are also found in the 
brains of aged individuals who have never displayed 
signs of dementia. For example, a recent article (J. Biol. 
Chem., 265:15977 (1990)) has shown that there were no 
differences in the primary structure of precursor amy 
loid protein from platelets of normal individuals and 
that of Alzheimer’s disease patients. Therefore, while 
amyloid protein may be involved in Alzheimer’s dis 
ease, other methods have been pursued to identify char 
acteristics more uniquely related to a patient with Alz 
heimer’s disease. For instance, U.S. Pat. No. 4,727,041, 
issued to Aroonsakul, discloses a comparative test for 
the diagnosis of Alzehimer’s disease in humans by deter 
mining levels of somatotropin and somatomedin-C in 
the patient’s blood sera drawn at intervals following 
administration of an L-dopa provocative test. 
Immunoassay methods have also been developed for 
detecting the presence of neurochemical markers in 
Alzheimer’s disease patients. U.S. Pat. Nos. 4,728,605 
and 4,801,533, issued to Fudenberg et al., disclose com 
parative methods for diagnosing degenerative disease of 
the central nervous system, particularly Alzheimer’s 
disease, by measuring immunological parameters and 
interactive T cells from a patient’s peripheral blood. 
U.S. Pat. No. 4,806,627, issued to Wisniewski et al., 
discloses protease resistant proteins which comprise 
scrapie-associated ?brils and a scrapie-speci?c mono 
clonal antibody to distinguish certain neurological dis 
ease-caused human dementias from Alzheimer’s disease. 
However, none of the known methods of diagnosis 
have proven to be a reliable means of detection of A12 
heimer’s disease in all patients, particularly at early 
stages of the disease. As a result, alternative methods of 
diagnosis have been proposed which rely on analyzing 
the cerebral spinal ?uid drawn from the affected pa 
tients. For example, Warner in Anal. Chem, 
59:1203A—l204A (1987), has proposed a method for 
detecting Alzheimer’s disease related amyloid protein in 
the cerebral spinal ?uid of affected patients. 
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US. Pat. No. 4,874,694, issued to Gandy et al., dis 
closes a diagnostic method for neurological and psychi 
atric disorders, such as Alzheimer‘s disease. The 
method involves incubating cerebrospinal ?uid from a 
patient in the presence of 32P-labeled adenosine triphos 
phate (ATP) and a protein kinase which was capable of 
transferring phosphate from the ATP, followed by elec 
trophoresis. The resulting autoradiographic pattern of 
the fractionated, labeled sample is then compared with 
predetermined autoradiographic patterns from known 
neurological and psychiatric pathologies to ascertain 
the particular pathology of the patient’s cerebrospinal 
?uid being analyzed. However, the method disadvanta 
geously is based only on autoradiographic patterns. It 
fails to identify disease-speci?c marker proteins in the 
cerebral spinal ?uid. 
Studies by Khatoon et al. (Ann. of Neurology, 
26:210-215 (1989)) have shown that an interaction of an 
important cellular protein, tubulin, in the formation of 
microtubules was aberrant in preparations made from 
the brain tissues of patients with Alzheimer’s disease. 
The inhibition was monitored by measuring the interac 
tions of a radioactive photoaf?nity probe of the nucleo 
tide GTP (guanosine-S’-tri-phosphate) with the proteins 
that require GTP to effect microtubule formation. 
Molecules containing azido groups have been shown 
to form covalent bonds to proteins through reactive 
nitrene intermediates, generated by low intensity ultra~ 
violet light. Potter & Haley, Meth. in Enzymol, 
91:613-633 (1983). In particular, 2- and 8-azido ana 
logues of purine nucleotides have been used as site di 
rected photoprobes to identify nucleotide binding pro 
teins in crude cell extracts. Owens 8; Haley, J. Biol. 
Chem. 259:14843-14848 (1984); Atherton et al., Bio. of 
Reproduction, 32:155-171 (1985). The 2-and 8-azido 
nucleotides have also been used to map nucleotide bind 
ing domains of puri?ed proteins. Khatoon et al., Ann. of 
Neurology, 26:210-215 (1989); King et al., J. Biol. 
Chem. 264:10210-10218 (1989); and Dholakia et al., J. 
Biol. Chem, 264:20638-20642 (1989). 
Photoaf?nity probes have been used to determine 
speci?c nucleotide binding sites on a biologically active 
recombinant peptide molecule. Campbell et al., PNAS, 
87:1243-1246 (1990). The probes have also been used to 
study enzyme kinetics of puri?ed proteins. Kim et al., J. 
Biol. Chem., 265:3636-3641 (1990). 
Thus, considerable effort has been devoted to devel 
oping systems for the de?nitive diagnosis of Alzhei 
mer’s disease in patients. However, until the method of 
the, present invention, no reliable non-invasive test for 
Alzheimer’s disease has been developed. The major 
drawback of the most de?nitive determination of Alz 
heimer’s disease known in the art has been that direct 
analysis of pathological tissue could only be performed 
postmortem on affected individuals. 
Because Alzheimer’s disease is progressive in nature, 
the ef?ciency of a cure could critically depend upon 
early detection. Additionally, the value of any new 
therapy in alleviating or curing the disease could be 
better ascertained if a rapid, safe and effective diagnos 
tic procedure were available to monitor the progress of 
Alzheimer’s disease patients following treatment. 
Therefore, there remains a long-felt need in the art 
for a reliable, accurate, safe and effective method for 
the diagnosis of Alzheimer’s disease, as well as a means 
for the differentiation of other neurological diseases and 
syndromes or psychiatric pathology. A method for the 
identi?cation and characterization of a disease-speci?c 
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biochemical marker and the identi?cation of such a 
marker is needed. 
OBJECTS AND SUMMARY OF THE 
INVENTION 
It is, therefore, an object of this invention to provide 
a method for diagnosing Alzheimer’s disease compris 
ing detecting a speci?c nucleotide binding protein 
within the extracted cerebral spinal fluid of patients 
afflicted with Alzheimer’s disease. 
It is another object of the present invention to pro 
vide a method for diagnosing Alzheimer’s disease com 
prising detecting a speci?c nucleotide binding protein 
within the extracted cerebral spinal ?uid of normal 
patients, but which is not photolabeled in they cerebral 
spinal ?uid of patients afflicted with Alzheimer’s dis 
ease. 
It is a further object of the present invention to pro 
vide a composition for use in a test kit for the diagnosis 
of Alzheimer’s disease comprising a radioactive pho 
toaf?nity probe which will selectively bind to a speci?c 
nucleotide binding protein within the extracted cerebral 
spinal ?uid of a patient af?icted with Alzheimer’s dis 
ease, but which is not found in the cerebral spinal ?uid 
of a normal subject. 
A still further object of the present invention is to 
provide a composition for use in a test kit for the diag 
nosis of Alzheimer’s disease comprising a radioactive 
photoaf?nity probe which will selectively bind to a 
speci?c nucleotide binding protein within in the cere~ 
bral spinal ?uid of a normal patient, but which is not 
found in the cerebral spinal ?uid of a patient af?icted 
with Alzheimer’s disease. , 
It is an additional object of the present invention to 
provide antibodies to the respective Alzheimer’s disease 
related proteins, as identi?ed by the method of the cur 
rent invention, for the purpose of providing an immuno 
assay to recognize the Alzheimer’s disease speci?c pro 
teins in the cerebral spinal ?uid, blood plasma, or tissues 
of the human body. 
It is a ?nal object of the present invention to provide 
a method, using the procedure of photoaf?nity labeling 
with nucleotide af?nity probes, to diagnose neurologi 
cal disorders using cerebral spinal ?uid, blood, tissue, or 
other biological samples from a mammal. The presence 
or development of a neurological or psychiatric pathol 
ogy including, but not limited to, Alzheimer’s disease, 
epilepsy, scrapies-type disorders, amyotrophic lateral 
sclerosis (ALS or Lou Gehrig’s disease), Down’s syn 
drome, Behcet disease, encephalitis, Huntington dis 
ease, Creutzfeldt-Jakob disease, Parkinson disease, 
AIDS dementia, multiinfarct dementia, dystonia, ataxia, 
schizophrenia, neurosyphilis, cerebral toxoplasmosis, 
brain irradiation, brain tumor, Guillain-Barre syn 
drome, tremor, multiple sclerosis, head trauma, acute 
and chronic encephalitic and vascular disease can be 
detected. 
Additional objects, advantages and novel features of 
the invention will be set forth in part in the description 
which follows, and in part will become apparent to 
those skilled in the art on examination of the following 
description, or may be learned by practice of the inven 
tion. 
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DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
In accordance with the present invention, novel com~ 
positions, methods and test kits are provided, using the 
procedure of photoaf?nity labeling with nucleotide 
af?nity probes, to detect a neurological disorder using 
cerebral spinal ?uid, blood, tissue, or other biological 
samples from a mammal. The presence or development 
of a neurological or psychiatric disorder can be de 
tected. The invention concerns a composition, the prep 
aration of the composition and a method for diagnosing 
or detecting Alzheimer’s disease. The method involves 
the use of a disease-speci?c nucleotide binding protein 
within the extracted cerebral spinal ?uid of a patient 
af?icted with a neurological disorder such as Alzhei 
mer’s disease. 
The present invention provides a method for detec 
tion using a disease-speci?c biochemical marker macro 
molecule which, if present, can be identi?ed in a small 
biological sample obtained from a patient. The speci?c 
biochemical marker macromolecule is dependent of the 
neurological disease state which is being detected. 
The standards are established by obtaining cerebral 
spinal ?uid samples from a number of patients, each of 
whom suffers from a particular neurological or psychi 
atric disorder which is clinically manifested by marked 
dementia or de?ciency in cognitive function, including 
memory or attention. 
Speci?cally the neurological diseases of the nervous 
system, referred to in the method of the present inven 
tion are those diseases, disorders, or syndromes which 
are either the cause of or the result of a biochemical 
alteration in the brain, brain stem. spinal cord or gan 
glia. The diseases can include, but are not limited to, 
Alzheimer’s disease, epilepsy, scrapies-type disorders, 
amyotrophic lateral sclerosis (ALS or Lou Gehrig‘s 
disease), Down’s syndrome, Behcet disease, encephali 
tis, Huntington disease, Creutzfeldt-Jakob disease, Par 
kinson disease. AIDS dementia, multiinfarct dementia, 
dystonia, ataxia, schizophrenia. neurosyphilis, cerebral 
toxoplasmosis, brain irradiation, brain tumor, Guillain 
Barre syndrome, tremor, multiple sclerosis, head 
trauma, acute and chronic encephalitic and vascular 
disease. Moreover, the present method of detection 
could also be used to monitor any event which causes 
brain cell death which results in the accumulation of 
nucleotide binding proteins in the cerebral spinal ?uids, 
such as, minor to severe brain damage caused by high 
fever or head injury. 
By the present invention it has been shown that a 
disease-speci?c unique biochemical marker macromole 
cule, in particular a speci?c nucleotide binding protein, 
can be identi?ed in the spinal ?uid of patients suffering 
from certain neurological disorders, particularly pa 
tients suffering from Alzheimer’s disease. 
Brie?y, a typical analysis of a cerebral spinal ?uid 
sample by the method of the present invention would 
proceed as follows. These steps and quantities are only 
offered as guidlines for the practice of the present in 
vention. 
A small portion, usually between 10 to 30 microliters 
of cerebral spinal ?uid is mixed with concentrations of 
about 10 to 30 uM of a radioactive photoaf?nity probe 
for 0.5 to 1.0 minutes. followed by 30 to 120 seconds of 
exposure to ultraviolet light. The sample is precipitated, 
then immediately solubilized with a solution containing 
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detergent and subjected to protein fractionation, such as 
by gel electrophoresis. The ?nished gel is placed in a 
holder containing X-ray ?lm for autoradiography. The 
radioactive protein (the result of chemical crosslinking 
between the radioactive photoprobe and the binding 
protein) in the gel can be located since the radioactivity 
will expose the adjacent section of the ?lm resulting in 
a darkened (black) appearance. 
The sample subjected to analysis can be selected from 
any biological sample capable of carrying the unique 
nucleotide binding protein. Examples of such biological 
samples include body ?uids such as spinal ?uid, blood 
or serum. However, samples tested for the unique nu 
cleotide binding protein by the present method are most 
preferably cerebral spinal ?uid, also referred to as cere 
brospinal ?uid. 
The protein composition of cerebral spinal ?uid is 
largely derived from serum proteins which leak into the 
subarachnoid space through imperfections in the blood 
brain barrier, such as the area postrema, and perhaps 
across the richly vascular choroid plexus, through 
which cerebral spinal ?uid is generated as an ultra?l 
trate. The cerebral spinal ?uid has signi?cantly fewer 
proteins than cytosolic fractions. Some proteins, such as 
immunoglobulins, may be generated in the subarach 
noid space during in?ammation. Since the cerebral 
spinal ?uid bathes the surfaces of cerebral and cerebel 
lar cortices, the caudate, brain stem and spinal cord, 
each of the structures contributes to the total cerebral 
spinal ?uid protein. 
The inventive method need not be limited to human 
patients, but may be extended to any mammal afflicted 
with certain neurological or psychiatric diseases or 
syndromes, such as scrapies or “Mad Cow" disease. 
The sample may be drawn as either ventricular cere 
bral spinal fluid or lumbar cerebral spinal ?uid. Occa 
sionally, however, sample proteins are concentrated by 
various procedures to better visualize the speci?c nucle 
otide binding protein. Vacuum procedures include, for 
example, lyophilization or Speed-vac concentration. 
Also, precipitation of cerebral spinal ?uid by ammo 
nium sulfate or polyethylene glycol could be used to 
concentrate the nucleotide binding proteins. Thus, there 
are a variety of techniques well known in the art that 
would be suitable in the practice of the present inven 
tion. 
Detection of a specific nucleotide binding protein can 
be accomplished by measuring a label crosslinked to the 
selected biochemical marker macromolecule after reac~ 
tion, photochemical or chemical crosslinking, and re 
moval of free probe. The particular label bound to the 
macromolecule will include, for example, a' radioactive 
nucleotide introduced by replacing an equivalent non 
radioactive atom with 32P, tritium, carbon-l4 or other 
radioactive atom or ligand analog modi?ed with a 
linker group to provide a linking site to the crosslinking 
molecule. A particularly preferred radioactive label in 
the present invention is a- or 732?. 
The ligand or linker group, if present on the speci?c 
biochetnical marker macromolecule, will have chemical 
characteristics or functionalities such that a small radio 
active nuclide labeled molecule, or a chromogenic, 
?uorogenic, or luminescent molecule, or a magnetic 
particle can be attached to the ligand or linker group. 
The ligand will have the chemical characteristics such 
that a receptor molecule is available or capable of being 
elicited, such as an antibody molecule to the ligand. The 
receptor molecule can be conjugated to a radioactive 
5,272,055 
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nuclide labeled molecule, or to a chromogenic, ?uoro 
genic, or luminescent dye molecule, or to a magnetic 
particle or to an enzyme system capable of generating a 
chromogenic, fluorogenic, and/or luminescent product 
via appropriate substrates. 
Most preferably the unique biochemical marker mac 
romolecule, particularly the speci?c nucleotide binding 
protein, is detected in the sample by a radioactively 
labeled photoaf?nity probe. A nucleotide photoaf?nity 
probe is a nucleotide derivative which has affinities for 
binding sites and biological activity comparable to the 
unaltered nucleotide. Exposure to certain wavelengths 
of light converts the analog to a very reactive interme 
diate, typically a nitrene or a carbene, which may result 
in covalent incorporation into the binding site if it is 
‘bound to a protein. . 
There are certain advantages to using photoprobes 
over conventional chemical probes. One advantage is 
that K,,,, K4, and K; values can be determined in the 
absence of activating light. Another advantage is that 
complex systems such as ribosomes, membranes, and 
whole cell sonicates can be studied. In this manner, an 
in vivo situation may be more closely approximated and 
information may be obtained that might otherwise be 
lost in a puri?ed system. 
Many nucleotide photoaf?nity probes may be synthe 
sized and used successfully. The photoaf?nity com 
pounds of the invention may include, for example, pu 
rine triphosphate azido analogs, which may be exempli 
?ed by adenine analogs, although guanine analogs can 
be substituted therefor. For example, purine binding 
sites may be effectively labeled by the following, and 
their 5'-mono-, di- and triphosphates: oligomers of a 
single azidoadenylyl species, such as, for example: 2 
azido or 2-azidoadenylyl(2'-5’)2-azidoadenylyl(2’-5')2 
azidoadenosine; 2-azido or 8-azidoadadenosine; 8 
azidoadenylyl(2’-5’)-8-azidoadenylyl(2’-5')8 
azidoadenosine: 8-azidoadenylyl(2’-5')-8 
azidoadenylyl(2'—5’)8-azidoadenylyl-(2'-5')8 
azidoadenosine; 2,8-diazidoadenylyl(2’—5')2,8 
diazidoadenylyl(2’—5')2,8-diazido-adenosine; 2,8 
diazidoadenylyl(2'—5')2,S-diazidoadenyly1(2’-5')-2,8 
diazidoadenylyl(2'-5’)-2,8-diazidoadenosine; also oligo 
mers of AMP and a single azidoadenylyl species, such 
as, for example: 2-azidoadenylyl(2’-5’)2-(2’—5‘)8 
azidoadenosine; adenylyl(2'~5’)8-azido~adenylyl( 
2'-5’)8-azidoadenosine; also oligomers containing more 
than one azidoadenylyl species, such as, for example: 
2-azidoadenylyl(2’—5’)8-azidoadenylyl(2'-5‘)2 
azidoadenosine; also oligomers resulting from any com 
bination of the monomers AMP, 2-azido-AMP, 8-azido 
AMP and/or 2,8-diazido-AMP, provided that at least 
one such monomer incorporated into the oligomer is an 
azido-AMP species. 
In addition photoaf?nity compounds of the invention 
may also include photoactive coenzyme analogs of 
NAD'*, exempli?ed by nicotinamide 2-azidoadenosine 
dinucleotide (2-azido-NAD+), or analogs of NADH, 
exempli?ed by nicotinamide Z-hydrazidoadenosine di 
nucleotide (2-azido-NADH). 
Alternately, guanine moieties can be de?ned in each 
of the exemplary compounds in place of the respective 
adenine moieties. Therefore, certain most preferred 
compounds of the present invention are synthesized 
from azidoguanosine 5’-triphosphates or combinations 
thereof, or from azidoguanisine 5’-triphosphates and 
ATP. The latter provides a (2’-5')oligomer containing 
both guanylyl and azidoguanylyl moieties. 
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Furthermore, photoaf?nity compounds of the present 
invention may also include, for example, pyrimidine 
derivatives. For instance, photoactive analogs of dUTP, 
such as 5-azido-2’-deoxyuridine 5'-triphosphate (5 
N3dUTP), may be synthesized from dUMP and provide 
a pathway for the synthesis of other useful S-substituted 
uridine nucleotides. The S-diazouridine nucleotides 
may, for example, serve as active-site-directed photoaf 
?nity probes or as substrates for polymerizing enzymes 
to generate additional photoactive nucleic acids which 
remain stable to extremes of pH and which remain ef 
fective photolabeling reagents in the presence of reduc 
ing agents. Moreover, since the synthesis of 5-N3dUTP 
employs mild conditions, it is also possible to synthesize 
homopolymers of 5-N3dUTP to provide single-stranded 
photoactive DNA of de?ned length. Using 5N3UTP 
one can similarly produce photoactive RNA. 
Generalized methods for the synthesis of aryl azides 
include nucleophilic displacement of a bromine, chlo 
rine or nitro group by an azide ion or the addition of 
sodium azide to an acidic solution containing a diazo 
tized primary aromatic amine. 
To date the most widely used 8-azidopurine is proba 
bly 8N3cAMP. One of the advantages of 8N3cAMP is 
that in mammalian systems there are only two types of 
proteins that are known to bind cAMP with high af?n 
ity, the cAMP phosphodiesterases and the regulatory 
subunits of the cAMP-dependent protein kinases. The 
photoprobes [32P]8N3cAMP and [32P]8N3ATP have 
been employed to study, for example, the mechanisms 
of action of cAMP-dependent protein kinase. Photoac 
tive analogs of GTP, e.g., [32P]8N3GTP, have been 
developed to study, for example, tubulin polymeriza 
tion, while photoactive analogs of UTP, e.g., 
[32P]5N3dUTP have been generated to study, for exam 
ple, the binding site of DNA binding proteins. 
Preferred compounds of the present invention are 
synthesized from azidoadenosine 5’-triphosphates or 
combinations thereof, which provide a (2’-5’)oligomer 
containing both adenylyl and azidoadenylyl moieties. A 
preferred photoaf?nity compound for the identi?cation 
by the present invention of the Alzheimer’s disease 
speci?c protein is 8-azidoadenosine 5'-triphosphate 
(8N3ATP), while a particularly preferred photoaf?nity 
compound of the present invention is 2-azidoadenosine 
5'-triphosphate (2N3ATP). A particularly preferred 
photoaf?nity compound for the identi?cation by the 
present invention of the ALS-speci?c protein is 8 
azidoguanosine 5’-triphosphate (8N3GTP). 
Nonradioactive labels can be divided into two cate 
gories (i) chromogenic, ?uorogenic, or chemilumines 
cent dyes or (ii) ligands. Dyes are normally of from 8 to 
40 carbon atoms, preferably from 9 to 30 carbon atoms. 
The dyes further normally contain from 1 to 10 hetero 
atoms usually oxygen, nitrogen, or sulfur, and normally 
contain no halogen atoms or up to 10 halogen atoms 
usually iodine, bromine, chlorine, or ?uorine. 
Chromogenic dyes may include phenolsulfonphthal 
ein and analogs of tetrazolium. 
Fluorogenic dyes may include ?uorescein isothiocya 
nate, dichlorotriazinylamino ?uorescein, morpholinor 
hodamine isothiocyanate, tetramethylrhodamine isothi 
ocyanate, and 4-acetamido-4-isothiocyanostilbene-2 
with 2’-disulfonic acid. Fluorescent purine derivatives 
may also include, for example, the fluorescent GTP 
analog 2'3'-O~(2,4,6-trinitrocyclohexadienyl-idine) 
guanosine 5'-triphosphate (TNP-GTP), or the equiva 
lent ?uorescent ATP derivative (TN P-ATP). 
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Chemiluminescent dyes may include 5-amino-2,3 
dihydro-phthalazine-l,4-dione (luminol), derivatives of 
isoluminol and acridinium esters. 
Any ligand may be employed for which an appropri 
ate receptor may be found to have satisfactory speci?c 
ity for the ligand. 
Various methods or protocols may be employed in 
measuring the amount of the labels. These protocols can 
include for example, radioimmunoassay (RIA), im 
munoradiometric assay (IRMA), sandwich IRMA, 
?uoroimmunoassay (FIA), chemiluminescent assays, 
bioluminescent assays, and enzyme linked immunosorb 
ent assays (ELISA) among others. 
The labeled probe of the present invention can be 
used in any conventional hybridization technique. Hy 
bridization formats which may be useful in the practice 
of the present invention include those in which the 
sample is immobilized on a solid support (solid-phase 
hybridization) and those wherein the species are all in 
solution (solution hybridization). Solution hybridization 
is preferred in the present method. Another method of 
interest is the sandwich hybridization technique. 
Certain factors are considered when a unique bio 
chemical macromolecular marker is identi?ed by means 
of a radioactive photoaf?nity label, as is the preferred 
method of the present invention. For example, consider 
ation should be given to: (a) temperature of incubation 
and photolysis, (b) length of incubation and photolysis, 
(c) concentration of photoaffmity reagent, (d) binding 
af?nity of protein for the reagent and natural ligands, 
(e) stability of the photoaf?nity reagent in each particu 
lar system, (f) ionic strength, pl-l, cofactors, (g) protein 
concentration, (h) intensity of photolyzing light, (i) 
quenching of reaction and separation of unused label, 
and (j) interpretation of results. Potter 8: Haley in Meth. 
in EnzymoL, 91:613-633 (1983) provide a detailed ac 
count of preferred procedures for labeling a speci?c 
biochemical marker macromolecule in a sample with a 
photosensitive purine triphosphate azide analog. 
Temperature of the photolysis reaction between the 
sample and the selected photoaf?nity label can range 
from 0c C. to room temperature (25° C.) or above. How 
ever, the exchange rate between bound and unbound 
cAMP or 8-N3cAMP approaches negligible levels at 0° 
C., and is greatly increased at room temperature. Con 
versely, once 8-N3CAMP is bound to the speci?c mac~ 
romolecular marker, it may be cold trapped onto the 
protein by dropping the temperature to nearly 0° C. 
Therefore, the most preferred procedure includes prein 
cubation of the components at room temperature, and 
photolysis in plates set on ice to reduce the temperature 
to approximately 0° to 4° C. By the present invention, 
the sample is preferably incubated at room temperature 
with the radioactive photoaf?nity probe for approxi 
mately 0.5 to 1.0 minutes. Most preferably the mixture is 
vortexed for 6 seconds followed by an additional 24 
seconds of mixing, immediately followed by placing the 
sample on ice for photoactivation. 
The concentration of photoaf?nity reagent must be 
compatible with the binding af?nity of the protein to be 
labeled. Excessively high concentrations, however, can 
lead to undesirable nonspeci?c labeling which increases 
linearly with concentration. Best results can be obtained 
by experimentally determining the optimum concentra 
tion for photoincorporation. Directly related to the 
determination of concentration is the stability of the 
reagent. The stability of the reagent can be determined 
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by thin-layer chromatography, e.g., by ?uorescent cel 
lulose thin-layer chromatography. 
Ionic strength, pH, cofactor, and metal ion concen 
trations can each affect protein structure, and are 
readily adjusted by those skilled in the art to achieve 
optimal labeling conditions. In addition protein concen 
tration can be determinative of the photoresponse. The 
higher the protein content of the sample, the denser the 
solution becomes to light. Therefore, in a denser solu 
tion, less UV light reaches the photoreagent per unit of 
time, decreasing the rate of photoincorporation. Aggre 
gation of the protein can also affect the binding time of 
the reagent to the protein, thereby increasing or de 
creasing photoincorporation. One must experimentally 
redetermine optimal photolysis time when changing 
protein concentration if maximum incorporation of the 
photolabel is desired. 
By the present invention, it is preferable to photolabel 
a small 10 to 30 microliter aliquot of cerebral spinal ?uid 
with radioactively-labeled photoaf?nity probe (i.e., 
[32P]2N3ATP or [32P]8N3ATP) resulting in an approxi 
mate ?nal concentration of 10 to 30 uM for detection of 
the Alzheimer’s disease-speci?c 42,000M, protein. Most 
preferably, the aliquot of each cerebral spinal ?uid ana 
lyzed is 15 ul. However, limits of detection are im 
proved, at little expense, by using larger sample vol 
umes or by concentrating the spinal ?uid. 
In the alternative, the sample may be labeled with 
[32P]8N3cAMP, in which case the sample is placed on 
ice to reduce the temperature to about 0° C. and photo 
activated. In experiments conducted to evaluate the 
absence of [32P]8N3cAMP photoinsertion into the pro 
tein of interest in a cerebral spinal ?uid sample, the 
preferred concentration of [32P]8N3cAMP is main 
tained at not more than 5 uM. 
Detection of the labeled protein occurs following an 
appropriate, predetermined incubation time to effect a 
reaction, and is calculated on the basis of the sample and 
the selected photoaf?nity probe. 
The intensity of the photolyzing light is such that 
maximum photoincorporation can be obtained in a mini 
mum amount of time without appreciable change in 
temperature or damage to the biological sample. Prefer 
ably the photolysis is achieved at 254 nm with an ultra 
violet light source. 
Ultraviolet (UV) light is essential for the activation of 
the photoprobe treated samples, but only a low intensity 
UV light is necessary. The intensity of the UV light can 
range from 180 to 800 uW/cm2 by conventional sources 
to 4000 uW/cm2 and above when a high intensity 
source is used to achieve rapid photolysis. 
Photolysis times range from 15 seconds to 5 minutes 
and must be experimentally determined for each reac~ 
tion system. For lamps having intensities of l80—800 
uW/cm2, the preferred photolysis time ranges from 
approximately 30 to 120 seconds, most preferably, pho 
tolysis is effected in approximately 30 to 60 seconds. 
The distance of the light source from the sample is a 
determinative factor in the conditions of photolysis. A 
preferred method of the present invention uses an ultra 
violet light source having suf?cient intensity, about 
6200 uW/cmZ, positioned at a set distance, about 1 cm 
from the sample, for a time sufficient to effect photoac 
tivation, generally approximately 45 seconds. 
The labeled macromolecule is typically separated 
from the solution containing excess unbound sample 
and/or label by precipitation, although other recog 
nized methods of protein puri?cation are possible. Rec 
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ognized methods of precipitation include, but are not 
limited to addition of an effective protein precipitating 
agent, such as trichloroacetic acid (TCA), perchloric 
acid (PCA), acetone, ammonium sulfate, polyethylene 
glycol (PEG) or the like to the sample. PCA or ammo 
nium sulfate are the preferred precipitating agents in the 
present method, and PCA is the particularly preferred 
precipitating agent. 
The amount of precipitating agent is determined by 
the concentration of protein in the sample. The pre 
ferred concentration of the precipitating agent is that 
concentration which effectively precipitates the spe 
ci?c protein from solution. The most preferred concen 
tration of the precipitating agent is that amount which 
effectively precipitates the previously activated, 
photolabeled cerebral spinal ?uid sample. 
The precipitating agent can be mixed with the sample 
as a dry batch addition or in a calculated equivalent 
liquid form. The required mixing time may vary with 
the nature of the agent selected and the size or concen 
tration of the sample. However, the time required is that 
point after which essentially no additional protein is 
precipitated from the sample solution at the tempera 
ture selected. 
The precipitated protein may be separated from solu 
tion by any effective means, such as centrifugation, 
sedimentation or ?ltration. The preferred method of 
separation of the precipitated protein from the solution 
is by centrifugation at a suf?cient speed and for a suffi 
cient time to effectively isolate the protein into a pellet. 
The most preferred method of separation is centrifuga 
tion at 13,000 X G for 30 minutes. However, the parame 
ters vary with the nature of the solution. 
To determine the effectiveness of the precipitation 
and separation procedures, both the pellet and the su 
pernatant ?uid are analyzed for protein content. 
The precipitated protein may be solubilized and any 
remaining reaction quenched by any effective, known 
method. The determination of the solubilizing agent 
would depend on the ultimate method of identifying the 
speci?c nucleotide binding protein. Therefore, such 
agents could include, e.g., sodium dodecyl sulfate 
(SDS) or urea, and certain stabilizing agents. 
Any azide remaining after photolysis may be de 
stroyed by the addition of dithiothreitol or its equiva 
lent, and potential phosphotransfer from the tn'phos 
phate derivative N3ATP or N3GTP may be inhibited 
by chelators such as EDTA. The preferred protein 
solubilizing agent is a detergent, particularly SDS, most 
preferably in a protein solubilizing mix (PSM), such as 
described by Potter & Haley in Meth. in Enzymol., 
91:613-633 (1983) or by procedures standard to most 
published procedures. A particularly preferred concen 
tration of SDS in the mix is 10%, resulting in a concen 
tration of SDS to the ?nal sample of 4%. 
Solubilization can occur either at 0° C. or at higher 
temperatures without affecting the results. However, 
solubilization in the present invention is effective at 
room temperature. 
Upon solubilization, the protein sample is applied to a 
suitable support for separation of the protein fractions. 
Support materials could include, e.g., polyacrylamide 
gels, ?lter paper, starch gels or blocks, cellulose or 
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polyurethane foam. Any effective, known method of 65 
protein separation may be used, but preferably separa 
tion is by electrophoresis over denaturing or non 
denaturing gels, or over a gradient of either type. In the 
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present method, protein separation is usually by electro 
phoresis on a denaturing gel. 
The nature of the sample and the size of the speci?c 
nucleotide binding protein determine the concentration 
of the gel used, which in turn determines the time for 
separation and the electrical current which must be 
applied to best achieve protein separation. The protein 
fractions of the present invention are most preferably 
separated by electrophoresis on an SDS-polyacryla 
mide gel (SDS-PAGE). Typically, the sample is frac 
tionated on a 10% polyacrylamide gel, run over a per 
iod of 2} to 3 hours, with constant amperage of 35 mA 
and an initial voltage of about 140 volts. Any standard 
electrophoresis equipment can be utilized. ' 
The resultant gels are exposed to X-ray ?lm and 
visualized by autoradiography according to methods 
well known in the art. The gels can also be stained to 
determine the presence of the unique specific protein 
band or to ascertain that differences in the amount of 
photolabel incorporation are not due to drastic changes 
in the protein levels. Many known protein staining 
methods are widely recognized, e.g., Coomassie Bril 
liant Blue R (CBB) or silver staining. CBB is a com 
monly used stain that detects proteins based on a hydro 
phobic interaction between the proteins and the dye. 
Although any available staining method can be used 
which effectively distinguishes the speci?c nucleotide 
binding protein, CBB is the fastest and most economical 
for the present method. 
Most preferably, each completed SDS-PAGE gel is 
stained with an effective amount of CBB to stain the 
selected protein fragments. In particular, the completed 
gel is immersed in a 10% CBB (w/v) solution for about 
1 hour. Then the gel is destained in a solution to effec 
tively remove excess stain. Particularly preferred is a 
destaining solution of 5% acetic acid and 10% isopropyl 
alcohol applied for 10-18 hours. 
Finally, the speci?c binding protein fragments may 
be visualized by standard autoradiography techniques. 
The use of an intensifying screen effectively accelerates 
the visualization process of autoradiography. By the 
method of the present invention, the stained gel is dried, 
and then exposed to DuPont Cronex 4 X-ray ?lm. The 
autoradiographic procedure is for variable time periods 
depending on the speci?c activity of the probe photoin 
serted into the proteins of each experimental sample. 
Alternately, if maintained at —70° C., the gel can be 
subjected to autoradiographic procedures while still in 
the gel state. 
The amount of protein, as well as the radioactivity 
incorporated into each protein, can be quanti?ed by 
known methods including, but not limited to, densito 
metric scans of the exposed X-ray ?lm, or of the stained 
gel, or by liquid scintillation spectrometry of the protein 
band following excision from the gel. 
Analyses of cerebral spinal fluid taken from human 
patients suffering from certain neurological or psychiat 
ric diseases or disorders, when labeled with the appro 
priate, subsequently activated, radioactive photoaf?nity 
probe, reveals a disease-speci?c biochemical marker by 
which an existing disease state can be characterized. 
For example, a protein band having an apparent molec 
ular weight of about 68,000 Dil0% is found in the 
cerebral spinal ?uid of normal human subjects, visual 
ized by a subsequently activated, radioactive photoaf 
?nity probe, e.g., [32P]8N3cAMP. More particularly, 
the identi?ed protein band has an approximate molecu 
lar weight of 68 kD. Moreover, a fragment of the same 
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size is recognized in cerebral spinal ?uid samples taken 
from patients af?icted with neurological diseases other 
than Alzheimer’s disease. 
By comparison, the cerebral spinal ?uid of human 
patients suffering from Alzheimer’s disease, is charac 
terized by an absence of photodetection of the protein 
fragment having an approximate weight of 68 kD, as 
visualized by photolabeling by, for example, 
[32P]8N3cAMP. 
Furthermore, the cerebral spinal ?uid of human pa 
tients suffering from various neurological and psychiat 
ric disorders, labeled with a subsequently activated, 
radioactive photoaf?nity probe, is found to have unique 
speci?c nucleotide binding proteins which can provide 
a distinctive means of diagnosing particular diseases. 
For example, a characteristic protein band having an 
apparent molecular weight of about 42,000 D;+:10% is 
found in the radioactive photoaf?nity labeled cerebral 
spinal ?uid of Alzheimer’s disease patients using 
[32P]8N3ATP. More particularly, the Alzheimer’s dis 
ease-speci?c identi?ed protein band has an approximate 
molecular weight of 42 kD. 
By comparison, a systematic survey of the cerebral 
spinal ?uid taken from normal human subjects and la 
beled with a similar subsequently activated, radioactive 
photoaf?nity probe (i.e., [32P]8N3ATP), shows no pro 
tein fragment having an approximate weight of 42 kD 
being photolabeled. Thus, the identi?ed protein is 
unique to Alzheimer’s disease patients. There is appar 
ently no identi?ed corresponding protein fragment con 
tained in the cerebral spinal ?uid of normal human 
subjects. 
In addition to being photolabeled with the radioac 
tive photoprobe, the 42,000 M ,protein may be shown to 
interact with ATP, a naturally occuring nucleotide that 
is the phosphate donor for many protein kinases and 
synthetases. Therefore. based on the selectivity, the 
Alzheimer's disease-specific protein may be identi?ed as 
an ATP binding protein of about 42,000 M,. Further 
more, the same 42 kD protein can be photolabeled with 
8-azido-GTP, de?ning the speci?c protein as an ATP 
and GTP binding protein. However, the 42,000 M, 
protein binds ATP with higher af?nity. 
Therefore, the human cerebral spinal ?uid samples 
can be reliably and accurately distinguished into two 
groups. The cerebral spinal fluid samples taken from 
Alzheimer's disease patients show photoinsertion of 
[32P]8N3ATP or [32P]2N3ATP into the identi?ed dis 
ease-speci?c 42 kD protein, but an absence of photoin 
sertion of [32P]8N3cAMP in the normal 68 kD protein. 
Whereas, the samples taken from control subjects, unaf 
?icted by Alzheimer’s disease, show photoinsertion of 
[32P]8N3cAMP into a normal 68 kD protein, but no 
photoinsertion of either [32P]8N3ATP or [32P]2N3ATP 
into a 42 kD protein. The comparative analyses of cere 
bral spinal ?uid samples from Alzheimer’s disease pa 
tients and from normal human subjects, photolabeled 
with a GTP analog, confirm the results observed when 
the 42 kD protein is photo-labeled with the photoaf 
?nity probe of ATP. 
Based on mixing experiments of cerebral spinal ?uid 
taken from control subjects (in which the 68 kD protein 
is photolabeled) and samples of Alzheimer’s disease 
patients‘ cerebral spinal ?uid (in which the 68 kD pro 
tein does not photolabel), it may be shown by the pres 
ent invention that a component of the Alzheimer’s dis 
ease cerebral spinal ?uid apparently prevents photola 
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beling of the 68 kD protein of normal, control sample 
cerebral spinal ?uid with [32P]8N3cAMP. 
By the present invention, the Alzheimer’s disease 
speci?c 42,000 M, protein could be further identi?ed as 
glutamine synthetase. Mammalian glutamine synthetase 
is an enzyme with 42,000 M, subunits that catalyzes the 
following reaction: 
glutamate +NH4+ ATP-glutamine +ADP+Pi 
Further, it has been suggested that metabolism of gluta 
mate is altered in Alzheimer’s disease (AD) since those 
sections of the diseased brain which have become dys 
functional show very low levels of glutamate. More 
over, the neuronal cells that die in Alzheimer’s disease 
patients are glutamate sensitive cells. _ 
Glutamine synthetase can also be detected by measur 
ing the enzymatic catalytic conversion of substrates to 
products. Recognized detection techniques include, for 
example, measuring the catalytic conversion of 
["C]glutamate to [14C]glutamine or [a32P ]ATP to 
[a32P]ADP. Such methods of measuring catalytic con 
version are applicable to the detection of the Alzhei 
mer’s disease-speci?c 42,000 M, protein of the present 
invention. 
The 42,000 M ,protein is present in the cerebral spinal 
?uid of Alzheimer’s disease patients in very small quan 
tities. However, other than albumin and a protein of 
about 28,000 M,, the 42,000 M, protein is the major 
protein known to photolabel with either 8N3ATP or 
2N3ATP at the concentrations used. Therefore, by 
using the technique of photoaf?nity labeling and the 
materials and methods of the present invention, it is 
possible to detect a very minor protein of cerebral spi 
nal ?uid that interacts with ATP and GTP, and which 
appears to be unique in the cerebral spinal ?uid of clini 
cally diagnosed Alzheimer’s disease patients. 
A recently completed set of studies by the inventor of 
the present application have permitted the optimization 
of photo-incorporation into a protein. Thus, it is now 
possible to label 10-15 microliters of sample with thou 
sands of cpms of 32F, signi?cantly enhancing the puri? 
cation of the protein and further improving its value as 
a diagnostic tool. 
Post-mortem studies have shown that the identi?ed 
42,000 M, protein present in Alzheimer’s disease pa 
tients photolabels at high levels in the ventricular cere 
bral spinal ?uid, but only at low levels in the lumbar 
cerebral spinal ?uid. However, since the method of the 
present invention advantageously permits identi?cation 
and puri?cation of the speci?c nucleotide binding pro 
tein from only minute microliter amounts of cerebral 
spinal ?uid, the labeled 42 kD protein can be detected in 
samples containing only very low levels of the protein. 
Additionally, recent results using 1 ml aliquots of lum 
bar cerebral spinal ?uids treated with 40% ammonium 
sulfate saturation gave a protein precipitate that con 
tained easily detectable amounts of the 42,000 M, pro 
tein on photolabeling with [32P]2N3ATP. This con?rms 
that lumbar cerebral spinal ?uid can be used in this 
diagnostic test. 
By a similar procedure, a protein band having an 
apparent molecular weight of about 55,000 D is found in 
the cerebral spinal ?uid of amyotrophic lateral sclerosis 
(ALS or Lou Gehrig’s disease) patients, visualized by a 
subsequently activated, radioactive GTP photoaf?nity 
probe. Moreover, the unique ALS-speci?c 55,000 M, 
5,272,055 
15 
protein is not found in the cerebral spinal fluid of either 
normal subjects or patients with Alzheimer’s disease. 
Therefore, the unique variations in the pattern of 
photolabeled protein fragments found in a small sample 
of a patient’s cerebral spinal fluid provides the key to 
identifying an existing disease state affecting the patient. 
The compositions, methods, and test kits of the present 
invention, when applied to minute amounts of cerebral 
spinal fluid sample, can photolabel and detect the dis 
ease-speci?c biochemical marker by which a particular 
disease state may be identi?ed in a patient. 
The novel method of the present invention incorpo 
rates a dual system of comparison in order to diagnose 
the disease state. It is not enough that a speci?c disease 
state is recognized simply by the apparent absence of a 
speci?c protein. A ‘conclusion based on only the ab 
sence of a result could prove erroneous. For example, 
the protein could actually be present, but not properly 
photolabeled because of procedural errors. 
By the present invention the diagnosis is based on 
both the presence of a unique disease-speci?c binding 
protein or biochemical marker in a sample of body ?uid 
from a diseased patient, and the absence of a “normal" 
binding protein or biochemical marker characteristi 
cally found in samples from normal subjects. Therefore, 
the present inventive method has met a long-felt need in 
the art for a reliable, accurate, safe and effective method 
which distinguishes Alzheimer’s disease patients from 
both normal subjects and patients afflicted with other 
neurological or psychiatric disorders or dementias. 
Moreover, the invention advantageously has also met 
the equally long-felt need for a reliable, accurate, safe 
and effective method to detect disease-speci?c bio 
chemical markers for other neurological syndromes or 
diseases, such as ALS, in a patient so afflicted. 
In order that those skilled in the art can more fully 
understand the present invention and advantages 
thereof. the following examples are set forth. These 
examples are given solely for the purpose of illustration, 
and should not be considered as expressing limitations 
unless so set forth in the appended claims. 
EXAMPLES 
Standard procedures and reagents were used in ac 
cordance with Maniatis et al. (1982) Molecular Cloning: 
A Laboratory Manual, Cold Spring Harbor Labora 
tory, New York. Speci?c techniques for the photoaf 
?nity labeling of speci?c nucleotide binding sites with 
purine phosphate azide analogs were used in accor 
dance with Potter & Haley, Meth. in Enzymol., 91: 
613-633 (1983). Approximate molecular weights were 
represented as migration rates (M,) values as estimated 
from plots of the migration rate versus the log molecu 
lar weight of commercial protein standards. Each sam 
ple was analyzed at least three times to ensure accurate 
results. 
Example l-Puri?cation of the Cerebral Spinal Fluid 
Protein 
The diagnostic proteins of the present invention were 
characterized using the results of blind assays of cere 
bral spinal ?uid samples from 40 patients having condi 
tions diagnosed as Alzheimer‘s disease, Parkinson‘s 
disease or epilepsy, and corresponding age matched 
controls. 
The cerebral spinal ?uid samples were stored at —20° 
C. for various periods of time without adversely affect~ 
ing the experiments. Experiments conducted on freshly 
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collected and immediately photolabeled cerebral spinal 
?uid displayed the same characteristics as frozen sam 
ples stored for extended periods of time. Fresh cerebral 
spinal ?uid samples were collected from cadavers 
within a few hours of death. Frozen samples were 
shipped on dry ice from suppliers, Eli Lilly, Inc. and 
Athena Neurosciences, then stored at —20° C. until 
assayed. For each experiment, the sample was thawed 
completely, an aliquot was withdrawn, then the sample 
was immediately refrozen and returned to ~20’ C. 
storage. Samples were handled with gloved hands at all 
times. 
Each assay was perfonned on 15 pl of cerebral spinal 
?uid. Although the amount of cerebral spinal ?uid 
tested remained constant for each experiment, the pro 
tein concentration of each sample varied to some de 
gree. However, the slight protein variation showed no 
effect on the outcome of the experiment. 
Occasionally, lumbar cerebral spinal ?uid samples 
from some Alzheimer’s disease patients contained too 
little of the 42,000 M, protein to be visualized. Those 
samples were concentrated using vacuum procedures, 
lyophilization or Speed-vac concentration, prior to 
photolysis or by precipitation of proteins by ammonium 
sulfate or polyethylene glycol or the like. 
Concentration increased the visibility of the 42,000 
M, protein in cerebral spinal ?uid samples from Alzhei 
mer’s disease patients, but did not make the correspond 
ing 42,000 M, protein band detectable in the cerebral 
spinal ?uid from normal, control subjects. Moreover, 
following the vacuum concentration procedure, the 
68,000 M, proteins no longer photolabeled with 
[32P]8N3ATP. However, the effect was shown not to be 
generalized since photolabeling of the 26,000 M, pro 
tein, apparently present in all cerebral spinal ?uid sam 
ples, did not decrease following vacuum concentration. 
As a result, the 42,000 M, protein was more readily 
visible since it was one of only two major photolabeled 
species. Usually 1 ml of the cerebral spinal ?uid sample 
was evaporated under vacuum conditions to a ?nal 
volume of about 0.2 to 0.3 ml, resulting in an increased 
detection of the 42,000 M,protein of about 3- to 5-fold. 
Ammonium sulfate precipitation of 40% saturation of a 
1 ml aliquot of lumbar cerebral spinal ?uid increased 
detection at least 10 to 20 fold. 
Each cerebral spinal ?uid sample was photolabeled 
with [32P]8N3ATP to identify the 42,000 M, protein. 
The cerebral spinal ?uid sample was comprised to cere 
bral spinal ?uid, buffer, and water. The photoprobes 
used in each experiment were prepared by the inventor 
according to the procedures disclosed by Potter and 
Haley in Meth. In Enzymol, 91:613-633 (1983). Probes 
were also available commercially through ICN Radio 
chemicals 2727 Campus Drive, Irvine, Calif. 92715. 
Several concentrations of [32P]8N3cAMP were used 
in the various experiments. The concentrations varied 
from 1 uM to 10 uM, but produced no signi?cant varia 
tion in the results. Photo-labeling differences were most 
apparent at low concentrations of [32P]8N3cAMP with 
the Alzheimer’s disease 68,000 M, protein, wherein the 
degree of photoinsertion was much less than that of the 
comparable control 68,000 M, protein. The decreased 
availability of the 68,000 M, protein in Alzheimer’s 
disease patient samples is very concentration depen 
dent, with virtually no observable photoinsertion below 
a 5 }LM concentration of [32P]8N3cAMP. 
In each experiment, photoprobe was added to the 
‘cerebral spinal ?uid sample and vortexed for 6 seconds. 
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Each treated sample was then allowed to mix for an 
additional 24 seconds at room temperature before expo 
sure to ultraviolet (UV) light. 
The treated samples were placed on ice and exposed 
to UV light for 45 seconds. The UV light source, a 
hand-held UV lamp with an intensity of 6200 uW/cmZ, 
was positioned 1 cm from the sample. The UV activa 
tion of the photoprobe labeled samples was always 
conducted at 0° C. 
The samples were precipitated by the addition of 6% 
perchloric acid or by the addition of increasing amounts 
of ammonium sulfate. Precipitation by ammonium sul 
fate was used to purify the protein for further character 
ization of the protein found in the Alzheimer’s disease 
cerebral spinal ?uid or for antibody production. The 
protein precipitated ‘by each ammonium sulfate addition 
was saved for electrophoretic analysis and autoradiog 
raphy. 
The percentage of ammonium sulfate that precipi 
tated the identi?ed protein was suf?ciently specific that 
it was used as a factor to characterize the protein and its 
properties. Therefore, by combining the ammonium 
sulfate precipitations from before and after photolabel‘ 
ing. the 42,000 M, protein was concentrated from large 
volumes of cerebral spinal ?uid. Simultaneously, most 
of the contaminating proteins were removed. 
The 42,000 M, protein was precipitated by a 40% 
ammonium sulfate saturation. The calculated amount of 
solid ultrapure ammonium sulfate necessary to result in 
40% saturation was added to each previously activated, 
photolabeled cerebral spinal ?uid sample. The mixture 
was stirred gently for 30 minutes at room temperature, 
then centrifuged in a table top centrifuge (13,000XG) 
for 30 minutes to separate the puri?ed protein. Small 
aliquots of each supernatant and pellet were analyzed 
for protein content by SDS-PAGE. 
The puri?ed protein samples were solubilized in a 
protein solubilizing mix (PSM), standard to most pub 
lished procedures. The concentration of SDS (sodium 
dodecyl sulfate) in the mix was 10%, resulting in a 
concentration of SDS to the ?nal sample of 4%. Sam 
ples were solubilized in each experiment at room tem 
perature. 
Each sample was fractionated by 10% SDS-PAGE, 
run over a period of 2% to 3 hours, with constant amper 
age of 35 mA and an initial voltage of 140 volts. Since 
all of the proteins were very well separated on a 10% 
gel, a gradient was not necessary. 
The completed SDS-PAGE gels were stained to 
detect the protein before exposing the gel to X-ray ?lm. 
Coomassie Brilliant Blue R (CBB) proved to be the 
fastest and most effective stain for protein detection in 
these experiments. Each completed SDS-PAGE gel 
was stained with a 10% CBB (w/v) solution for about 1 
hour, then destained in a solution of 5% acetic acid and 
10% isopropyl alcohol for 10-18 hours, then washed 
three times to remove that portion of the photoaf?nity 
label which had not crosslinked with the speci?c nucle 
otide binding protein. 
Finally, the stained gels were dried and exposed to 
DuPont Cronex 4 X-ray ?lm. The autoradiographic 
procedure involved variable time periods depending on 
the speci?c activity of the probe photoinserted into the 
proteins of each experimental sample, and the presence 
of an intensifying screen to accelerate visualization of 
the speci?c protein band. 
The quantity of protein, as well as the amount of the 
radioactivity incorporated into each protein, was quan 
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ti?ed by densitometric scans of the exposed X-ray ?lm, 
or of the stained gel, or by liquid scintillation spectrom 
etry of the protein band excised from the gel. Signi? 
cance was determined by analysis of variance at a rho 
level below 0.50. 
From among the 40 samples analyzed under blind 
condition, all 16 cerebral spinal ?uid samples from Alz 
heimer’s disease patients showed photo-insertion by 
[32P]8N3ATP into the 42,000 M, protein. By compari 
son, only two “control” samples showed photoinsertion 
into the 42,000 M, protein, but the samples were from 
subjects aged 86 & 94, who had not been identi?ed as 
free of Alzheimer’s disease. Only 3 samples, each pro 
vided by the same laboratory, failed to demonstrate 
photoinsertion as expected. Furthermore, the speci?c 
42,000 M, protein was found absent in the remaining 19 
cerebral spinal ?uid samples, consisting of about equal 
numbers of samples from control subjects or from pa 
tients affected by Parkinson disease or epilepsy. 
Example 2-Photolabeling of Cerebral Spinal Fluid 
Samples with ['y32P]8N3ATP. 
Comparative cerebral spinal ?uid samples were ob 
tained from Athena Neurosciences from patients known 
to have epilepsy, Parkinson’s disease or Alzheimer’s 
disease (AD), or from normal control subjects. The 
samples were processed, photolabeled with 
['y32P]8N3ATP and analyzed according to the proce 
dures of Example 1. However, in an autoradiograph of 
an SDS-PAGE gel on which the proteins in the cere 
bral spinal fluid samples were screened in a blind man 
ner, a protein of about 42 kD was photolabeled only in 
the samples from Alzheimer’s disease patients. 
Example 3-Photolabeling of Cerebral Spinal Fluid 
Samples with [32P]8N3cAMP. 
The comparative cerebral spinal ?uid samples were 
the same as those used in Example 2, from patients 
known to have epilepsy, Parkinson’s disease or Alzhei~ 
mer’s disease (AD), or from normal control subjects. 
The samples were processed, photolabeled with 
[32P]8N3cAMP and analyzed according to the proce 
dures of Example 1. 
Two matched SDS-polyacrylamide gels were run to 
separate the cerebral spinal ?uid proteins in each sample 
after photolabeling with [32P]8N3cAMP. Gel I was 
stained with CBB, then exposed to X-ray ?lm and ana 
lyzed by autoradiography. Gel ll was stained and ana 
lyzed by autoradiography. 
The CBB stained gel showed that there were several 
proteins found in the cerebral spinal ?uid. The protein 
levels did not change when comparisons ‘were made 
between Alzheimer’s disease and control samples. 
However, by comparison, the autoradiographs show 
that the amount of [32P]8N3cAMP photolabel incorpo 
rated into each protein did vary between Alzheimer’s 
disease and control samples. Notably, more bands ap 
peared on the stained gel than on the exposed X-ray ?lm 
because not all cerebral spinal ?uid proteins were sub 
ject to photoinsertion. A protein of about 68 kD was 
photolabeled only in the samples from patients diag 
nosed as not having Alzheimer’s disease. In contrast, a 
protein of 42 kD was photolabeled with [3ZP]8N3ATP 
only in samples from Alzheimer’s diseased patients. 
The differences between the stained gel and the ex 
posed autoradiographic ?lm demonstrated that photola 
beling of a protein is a very speci?c and reproducible 
process. The experiments have shown that each 
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photolabeled disease-speci?c protein band has essen 
tially the same M, value, with slight variations due only 
to minor variations in the gel itself. 
Example 4-Puri?cation of the Alzheimer’s 
Disease-Speci?c 42 kD Binding Protein. 
The 42 kD cerebral spinal ?uid protein was isolated 
as a pure fraction by the following high performance 
liquid chromatography (HPLC) procedure. The cere 
bral spinal ?uid from Alzheimer’s disease patients was 
photolabeled and the protein fraction was precipitated 
by ammonium sulfate at 20 to 40% saturation. The 
precipitated proteins were solubilized in Buffer A [0.1% 
tri?uoroacetic acid (TFA)] and subjected to HPLC on 
a C4 column with the following acetonitrile gradient: 
0-20 minutes at 0% buffer B; then 20-80 minutes at 
increasing percentages of buffer B to 100%, wherein 
buffer B was 0.1% TFA and 70% CH3CN (acetoni 
trile). 
The 42 kD protein was eluted at approximately 
82-92% B. The fraction was also radioactive if the 
sample was photolyzed with [32P]2N3ATP or [-y 
32P]8N3ATP prior to the ammonium sulfate precipita 
tion. The purity and identity of the fraction was con 
?rmed by SDS-PAGE of the fraction and autoradio 
graphic visualization. Therefore, it was concluded that 
the puri?ed protein was subject to photoinsertion and 
had a molecular weight of 42,000 kD. 
Example S-Identi?cation of the Alzheimer’s 
Disease-Speci?c 42,000 M, Protein Found in Cerebral 
Spinal Fluid. 
Based on the following evidence, the Alzheimer’s 
disease-speci?c 42 kD protein detected by the method 
of the present invention in the photoaf?nity labeled 
cerebral spinal ?uid from Alzheimer‘s disease patients is 
mammalian glutamine synthetase (GS). - 
1. Puri?ed GS (purchased from Sigma, puri?ed from 
sheep brain) comigrated on SDS-PAGE identically 
with the 42,000 M, protein in the cerebral spinal ?uid 
from Alzheimer’s disease patients. 
2. Puri?ed GS and the 42 kD protein found in the 
cerebral spinal ?uid from Alzheimer’s disease patients 
had the same approximate saturation and Kd values for 
binding ATP, 8-azido-ATP and 2-azido-ATP. That is, 
both proteins showed saturation of photoinsertion by 
40-50 uM with half maximal photoinsertion occurring 
at about 10 uM with both 2-azido-ATP and 8-azido 
ATP. Also, ATP decreased the photolabeling of both 
proteins, with either 8- or 2-azido-ATP, at nearly identi 
cal concentrations of ATP. Therefore, both GS and the 
42 kD protein in the cerebral spinal ?uid from Alzhei 
mer’s disease patients had the same nucleotide binding 
properties. 
3. Photolabeling of puri?ed GS and the 42 kD protein 
found in the cerebral spinal ?uid from Alzheimer’s dis 
ease patients exhibited the same kinetic properties upon 
addition of certain ligands known to affect the kinetics 
of GS with regards to binding of nucleotides. More 
speci?cally, the addition of 100 mM ammonium bicar 
bonate enhanced the binding of [32P]2N3ATP, and 
therefore the photolabeling of both the 42 kD cerebral 
spinal ?uid protein and GS, by about 5-fold. Also, addi 
tion of 10 mM glutarate (a glutamate substrate analog) 
slightly decreased the binding of [32P]2N3ATP, and 
therefore slightly decreased the photolabeling of both 
the 42 kD cerebral spinal ?uid protein and GS in the 
presence of excess ammonium bicarbonate. 
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4. A nearly identical mole to mole ratio of photoinser 
tion was noted with both GS and the cerebral spinal 
?uid 42 kD protein from Alzheimer’s disease patients. 
Both' proteins showed the same relative photoinsertion 
ef?ciencies of 8-azido-ATP versus 2-azido-ATP. In 
particular, the amount of photo-incorporation into both 
GS and the 42kD protein found in the cerebral spinal 
?uid from Alzheimer’s disease patients was greater on a 
mole to mole basis when [732P]2N3ATP was used as a 
photolabel, rather than the structurally different ATP 
analog ['y32P]8N3ATP. 
5. Both puri?ed GS and the 42kD protein found in 
the cerebral spinal ?uid from Alzheimer’s disease pa 
tients were labeled with a secondary radioiodinated- > 
antibody known to be reactive to an antibody selective 
for GS (rat brain) in a Western blot. However, other 
cerebral spinal ?uid proteins and creatine kinase did not 
crossreact with this GS antibody. Therefore, antibody 
selective for GS also reacted with the 42kD protein of 
the cerebral spinal ?uid from Alzheimer’s disease pa 
tients. 
6. The elution pattern of both the 42kD protein and 
puri?ed GS was nearly identical on HPLC chromatog 
raphy using a C4 column and acetonitrile gradient as 
described in Example 4. Both eluted at about 75-85% 
buffer B. 
7. On 2-dimensional gel electrophoresis (IEF X SDS 
PAGE) the 42kD protein in the cerebral spinal ?uid 
from Alzheimer’s disease patients was a single species, 
having a pI value of 60:02 pH units. By comparison, 
with the puri?ed GS from Sigma the pl range of the 
major protein species at 42,000 M, value was 5.8-7.2 
and consisted of 6 isoelectric forms. The most acidic of 
the isoelectric forms migrated on 2-dimensional gels 
identically with the 42kD photolabeled protein in the 
cerebral spinal ?uid from Alzheimer’s disease patients. 
EXAMPLE 6-Development of an Immunoassay for the 
Disease-Speci?c Alzheimer’s Disease Protein. 
Levels of GS in brain homogenates from both nor 
mal, control subjects and Alzheimer’s disease patients 
were assayed in terms of immunological response to a 
G5 antibody. GS was determined to be greatly elevated 
in the samples from Alzheimer’s disease patients in com 
parison to the control samples. 
By the presently claimed method, it will be possible 
to isolate and purify the 42,000 M, protein for the spe 
ci?c production of both polyclonal and monoclonal 
antibodies. Furthermore, since the 42,000 M, protein is 
glutamine synthetase with a speci?c substrate, it will be 
possible to develop a biochemical assay for the presence 
of this enzyme based on GS’s catalytic properties. 
A reliable diagnostic test for Alzheimer’s disease 
requires the puri?cation and identi?cation of the spe 
ci?c protein unique to Alzheimer’s diseased patients. 
Production of antibodies to the speci?c protein will 
facilitate the development of immunoassay procedure. 
EXAMPLE 7-Photolabeling of Cerebral Spinal Fluid 
Samples from Amyotrophic Lateral Sclerosis and 
Alzheimer’s Disease Patients. 
Cerebral spinal ?uid samples from 4 patients known 
to have amyotrophic lateral sclerosis (lane ALS) were 
compared with samples from patients with Alzheimer’s 
disease (lanes AD). Each sample was processed, 
photolabeled with [732P]8N3ATP or [732P]8N3GTP 
and analyzed according to the procedures of Example 
1. 
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The autoradiograph of an SDS-PAGE gel on which 
the proteins in the cerebral spinal ?uid samples were 
screened, a speci?c protein of about 55,000 M, was 
photolabeled with ['y32P]8N3GTP only in the cerebral 
spinal ?uid samples from ALS patients. The 55,000 M, 
radiolabeled band was visible in each of the four sam 
ples of [32P]8N3GTP photolabeled cerebral spinal ?uid 
from ALS patients. Although the [32P]8N3GTP 
photolabeled bands, ALS #l, appeared to be about 
1/12 as intense as the corresponding protein bands, it 
was nevertheless detectable. 
By comparison, the [32P]8N3GTP photolabeled 55 
kD protein was not observed in cerebral spinal ?uid 
samples from Alzheimer’s disease patients or from sev 
eral other non-ALS subjects. Moreover, no detectable 
photoinsertion into ‘the Alzheimer’s disease-speci?c 42 
kD protein was found in the cerebral spinal ?uid sam 
ples from ALS patients. Therefore, the present method 
of photoaf?nity labeling with nucleotide af?nity probes 
to identify unique disease-speci?c proteins in the pa 
tient’s cerebral spinal ?uid was shown to be effective in 
the determination of the presence or development of 
certain human neurological diseases or syndromes. 
Although the present invention has been described 
with reference to the presently preferred embodiment, 
it should be understood that the skilled artisan may 
make various modi?cations, substitutions, omissions, 
and changes without departing from the spirit of the 
invention. Accordingly, it is intended that the scope of 
the present invention be limited only by the scope of the 
following claims. including equivalents thereof. 
What is claimed is: 
l. A method for aiding in the diagnosis of Alzhei 
mer’s disease in a mammal comprising: 
a) contacting a cerebrospinal ?uid sample which 
contains a nucleotide binding protein having an 
apparent M, of about 42,000 daltons. wherein said 
protein is glutamine synthetase, with an effective 
amount of a labeled ATP- or GTP-analog photoaf 
?nity-labeling reagent which speci?cally binds said 
nucleotide binding protein at the nucleotide bind 
ing site to photoaf?nity label said nucleotide pro 
tein: 
b) fractionating said cerebrospinal ?uid sample to 
separate the photoaf?nity-labeled nucleotide bind 
ing protein; 
c) detecting the presence of the separated photoaf?ni 
ty-labeled nucleotide binding protein; and 
d) correlating the presence of the photoaf?nity 
labeled nucleotide binding protein to the presence 
of Alzheimer’s disease. 
2. A method for aiding in the diagnosis of Alzhei 
mer’s disease in a mammal comprising: 
a) contacting a sample of cerebrospinal ?uid from a 
mammal which contains a nucleotide binding pro 
tein having an apparent Mrof about 42,000 daltons 
with an effective amount of labeled ATP- or GTP 
analog photoaf?nity-labeling reagent which specif 
ically binds said nucleotide binding protein at the 
nucleotide binding site to photoaf?nity label said 
nucleotide binding protein; 
b) precipitating the photoaf?nity-labeled protein 
from the sample using an effective amount of a 
precipitating agent; 
c) solubilizing the precipitated photoaf?nity-labeled 
protein; 
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d) subjecting the solubilized photoaf?nity-labeled 
protein to electrophoresis to separate the photoaf 
?nity-labeled protein; 
e) detecting the presence of the separated photoaf?ni 
ty~labeled protein; and 
f) correlating the presence of the photoaf?nity 
labeled protein to the presence of Alzheimer’s dis 
ease. 
3. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 1, wherein the labeled 
photoaf?nity labeling reagent is radioactively labeled. 
4. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 3, wherein the photoaf 
?nity labeling reagent is activated by an ultraviolet light 
sufficient to effect photoactivation. 
5. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 2, wherein the solubi 
lized photoaf?nity-labeled protein is separated by gel 
electrophoresis. 
6. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 3, wherein the radioac 
tively labeled photoaf?nity labeling reagent is [32F] 
8-azidoadenosine-5'-triphosphate ([32P]8N3ATP) or 
[32P]2-azidoadenosine-5’-triphosphate ([32P]2N3ATP). 
7. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 3, wherein the radioac 
tively labeled photoaf?nity labeling reagent is [321)] 
S-azidoguanosine-5’-triphosphate ([32P]8N3GTP) or 
[32P]2-azidoguanosine-5'-triphosphate ([32P]2N3GTP). 
8. The method for aiding in the diagnosis of Alzhei 
mer’s disease according to claim 2, in a patient af?icted 
with Alzheimer’s disease, wherein the sample contains 
no detected [32P]8N3cAMP photolabeled protein at an 
apparent M, of about 68,000 daltons. 
9. A method for aiding in the diagnosis of amyo 
trophic lateral sclerosis in a mammal comprising: 
a) contacting a cerebrospinal ?uid sample which 
contains a nucleotide binding protein having an 
apparent M, of about 55,000 daltons with an effec 
tive amount of labeled GTP~analog photoaf?nity 
labeling reagent which speci?cally binds said nu 
cleotide binding protein at the nucleotide binding 
site to photoaf?nity label said nucleotide binding 
protein; 
b) fractionating said cerebrospinal ?uid sample to 
separate the photoaf?nity-labeled nucleotide bind 
ing protein; 
0) detecting the presence of the separated photoaf?ni 
ty-labeled nucleotide binding protein; and 
d) correlating the presence of the photoaf?nity 
labeled nucleotide binding protein to the presence 
of arnyotrophic lateral sclerosis. 
10. The method for aiding in the diagnosis of amyo 
trophic lateral sclerosis according to claim 9, wherein 
the labeled photoaf?nity labeling reagent is radioac 
tively labeled. 
11. The method for aiding in the diagnosis of amyo 
trophic lateral sclerosis according to claim 10, wherein 
the photoaf?nity labeling reagent is activated by an 
ultraviolet light suf?cient to effect photoactivation. 
12. The method for aiding in the diagnosis of amyo 
trophic lateral sclerosis according to claim 10, wherein 
the radioactively labeled photoaf?nity labeling reagent 
is [32F]8-azidoguanosine-5’-triphosphate 
([32P]8N3GTP). 
13. A method for aiding in the diagnosis of Alzhei 
mer’s disease in a mammal comprising: 
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a) contacting a sample of cerebrospinal ?uid which 
contains a nucleotide binding protein having an 
apparent M, of about 42,000 daltons wherein said 
protein is glutamine synthetase, with a labeled anti 
body speci?c for glutamine synthetase under con 
ditions that allow the formation of glutamine syn 
thetase-antibody complex formation; 
b) detecting the presence of said glutamine synthe 
tase-antibody complexes; and 
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c) correlating the presence of said complexes with the 
presence of Alzheimer's disease. 
14. The method of claim 13, wherein the antibody 
speci?c for glutamine synthetase is labeled by binding 
to a second labeled antibody. 
15. The method of claim 14, wherein the glutamine 
synthetase-antibody complex formation is detected by 
enzyme linked immunosorbent assay, radioimmunoas 
say, immunoradiometric assay, sandwich immunoradi 
ometric assay, ?uoroimmunoassay, chemiluminescent 
assay, bioluminescent assay, or Western blot. 
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